HAPLN4 Antibody

What is HAPLN4 and what is its primary function in the brain?

HAPLN4 is a 40-42 kDa secreted member of the Link module superfamily, predominantly expressed in specific neuronal populations, particularly in the cerebellum and brainstem. It contains one Ig-like C2-type domain (amino acids 46-161) and two link domains (amino acids 163-365) .

HAPLN4 serves as a critical stabilizing component that mediates binding between hyaluronan and lecticans (particularly brevican) in perineuronal nets. This function is essential for:

• Formation and maintenance of the hyaluronan-associated matrix in the CNS

• Structural stabilization of neural networks

• Supporting proper neuronal conduction

• Development of perineuronal nets, which regulate neural plasticity

How do I select the appropriate HAPLN4 antibody for my experiment?

Selection should be based on experimental needs and target specificity:

Always confirm specificity: The R&D Systems polyclonal goat antibody (AF4085) shows less than 1% cross-reactivity with recombinant human HAPLN1 in Western blots .

Why is HAPLN4 detection challenging in certain brain regions?

HAPLN4 expression is highly region-specific, with predominant expression in:

• Medial nucleus of the trapezoid body (MNTB)

• Cerebellar regions

• Specific auditory pathways

Challenges arise from:

• Heterogeneous PNN composition between brain regions

• Age-dependent expression patterns

• HAPLN4 interactions with different binding partners across regions

• Lower expression levels in non-specialized brain areas

Research has demonstrated that inferior colliculus serves as a negative control region devoid of HAPLN4, making it useful for specificity validation .

What are the optimal tissue preparation methods for HAPLN4 immunohistochemistry?

For optimal HAPLN4 detection in brain tissue:

Fixation protocol:

• Immersion fixation in 4% paraformaldehyde for paraffin embedding

Antigen retrieval:

• For paraffin sections: Heat-induced epitope retrieval using either:

  • Antigen Retrieval Reagent-Basic (pH 9.0) (preferred)

  • Alternative: Citrate buffer (pH 6.0)

Blocking conditions:

• 5-10% normal serum (matching secondary antibody host)

• 0.1-0.3% Triton X-100 for enhanced penetration

Antibody incubation:

• Primary: Overnight at 4°C (goat anti-HAPLN4 at 3 μg/mL)

• Secondary: Anti-goat HRP-DAB or fluorescent-conjugated antibodies (2 hours at room temperature)

Counterstaining:

• Hematoxylin for brightfield microscopy

• DAPI for fluorescence applications

How can I design experiments to study HAPLN4 interactions with other perineuronal net components?

In situ proximity ligation assay (PLA) is the recommended approach for visualizing endogenous HAPLN4-lectican interactions:

• Sample preparation:

  • Use 5-month-old adult brain tissue sections (10-20 μm)

  • Include both wild-type and HAPLN4-KO tissues for controls

• PLA methodology:

  • Co-incubate sections with primary antibodies targeting:

    • HAPLN4 and brevican (to detect perisynaptic interactions)

    • HAPLN4 and aggrecan (to assess differential binding)

  • Include VGLUT1 as a synaptic marker for triple labeling

• Validation controls:

  • Negative control 1: Omit anti-HAPLN4 antibody on wild-type tissue

  • Negative control 2: Perform PLA for HAPLN4-brevican using HAPLN4-KO tissue

The PLA technique generates fluorescent dots only when target proteins are in close proximity (<40 nm), revealing physiologically relevant molecular associations between HAPLN4 and lecticans .

What methods are effective for quantifying changes in HAPLN4 expression across different experimental conditions?

Multiple complementary approaches are recommended:

• Western blot quantification:

  • Tissue homogenization in RIPA buffer with protease inhibitors

  • Protein concentration: 20-40 μg per lane

  • Detection: Anti-HAPLN4 (1:500-1:2400)

  • Normalization: β-actin or GAPDH

  • Densitometric analysis using ImageJ or similar software

• Immunofluorescence intensity analysis:

  • Z-stack confocal microscopy (0.5-1 μm steps)

  • Fluorescence intensity profiling along defined linear regions

  • Normalize signals to highest intensities of individual proteins

  • Assess colocalization with Manders' or Pearson's coefficients

• Real-time PCR:

  • Region-specific tissue microdissection

  • qPCR with HAPLN4-specific primers

  • Normalization to multiple housekeeping genes (GAPDH, β-actin)

All quantification should include:

• Blind analysis to prevent bias

• Multiple technical and biological replicates

• Appropriate statistical testing based on data distribution

How does HAPLN4 deficiency affect extracellular space diffusion parameters, and how can this be measured?

HAPLN4 deficiency significantly impacts extracellular space (ECS) diffusion parameters, particularly in aged animals:

Key findings:

• In young adult HAPLN4-KO mice (3-6 months): Minimal effects on ECS parameters

• In aged HAPLN4-KO mice (12-18 months): Significant decrease in extracellular space volume fraction

Measurement methodology: Real-time iontophoretic method

• Prepare acute brain slices from HAPLN4-KO and wild-type mice

• Insert iontophoretic and recording microelectrodes at defined distances

• Apply small current pulses to release tetramethylammonium (TMA+) as a diffusion marker

• Record TMA+ concentration changes over time

• Calculate ECS parameters:

  • Volume fraction (α)

  • Tortuosity (λ)

  • Non-specific uptake (k')

Complementary techniques:

• Immunohistochemical analysis of ECM composition

• Assessment of astrocyte morphology changes using GFAP staining

• Correlation of diffusion parameters with functional metrics

What is the relationship between HAPLN4 and neuropsychiatric disorders like schizophrenia?

HAPLN4 has emerged as a significant gene in schizophrenia research:

Genetic evidence:

• Identified in transcriptome-wide association studies by the PsychENCODE Consortium

• Among 108 schizophrenia-related loci identified by the Psychiatric Genomics Consortium

Neuroimaging correlations:

• HAPLN4 expression shows the largest negative correlation with gray matter volume (GMV) reduction in schizophrenia

• Lower expression is associated with more pronounced GMV reduction in specific brain regions

Hypothesized mechanisms:

• HAPLN4 deficiency may lead to destabilization of PNNs

• Altered PNN composition affects neuronal firing patterns

• Disrupted ECM organization influences synaptic plasticity

• Age-dependent effects accelerate neuropathology

Supporting evidence from animal models:

• HAPLN4-KO mice show decreased extracellular space volume fraction in aged brains

• PNN disruption alters neuronal excitability and circuit function

How can HAPLN4 antibodies be used to investigate the micro-organization of perineuronal nets at specialized synapses?

HAPLN4 antibodies enable detailed investigation of PNN micro-organization at specialized synapses, particularly the calyx of Held:

Multi-label immunofluorescence approach:

• Triple-label sections with:

  • HAPLN4 antibody

  • Lectican antibodies (brevican or aggrecan)

  • Synaptic marker (VGLUT1 for excitatory terminals)

• High-resolution confocal microscopy with:

  • Optimal optical sectioning (0.3-0.5 μm z-steps)

  • Deconvolution for enhanced resolution

  • Super-resolution techniques for nanoscale analysis

• Quantitative analysis:

  • Fluorescence intensity profiling along defined regions

  • Colocalization analysis at specific subcellular domains

  • 3D reconstruction of PNN architecture

Key findings at the calyx of Held:

• HAPLN4-brevican complexes localize primarily to the perisynaptic space between calyx terminals and principal neurons

• HAPLN1-aggrecan-tenascin-R complexes surround the entire calyx terminal

• In HAPLN4-KO mice, brevican shows ectopic expression in the surrounding neuropil, potentially stabilized by HAPLN1

This approach has revealed that distinct HAPLN proteins regulate PNN micro-organization through specific interactions with different lecticans .

How can I address variability in HAPLN4 antibody staining patterns between experiments?

Several factors contribute to variability in HAPLN4 antibody staining:

Common sources of variability and solutions:

Standardization approach:

• Include consistent positive controls (e.g., caudate nucleus for human samples)

• Process all experimental groups simultaneously

• Standardize image acquisition parameters

• Consider automated staining platforms for consistency

How do I interpret contradictory results between HAPLN4 localization studies at different synapses?

HAPLN4 shows synapse-specific localization patterns that can appear contradictory:

Reconciling conflicting observations:

• Region-specific differences:

  • MNTB: HAPLN4-brevican complexes predominantly in perisynaptic space

  • Cerebellum: HAPLN4 regulates GABAergic Purkinje synapses

  • Different regions express distinct brevican isoforms (secreted vs. membrane-bound)

• Methodological considerations:

  • Antibody epitope accessibility varies between preparations

  • PNN composition affects antibody penetration

  • Fixation protocols influence PNN preservation

• Biological heterogeneity:

  • Developmental stage affects HAPLN4 distribution patterns

  • Activity-dependent remodeling of PNNs

  • Species differences in PNN organization

Resolution approaches:

• Perform multi-technique validation (WB, IHC, IF, PLA)

• Include appropriate knockout controls

• Consider developmental time course analysis

• Use electron microscopy for ultrastructural localization

How can I design a rigorous experiment to determine whether HAPLN4 antibody staining is affected by post-translational modifications?

Experimental design to assess PTM effects on HAPLN4 detection:

• Sample preparation variations:

  • Enzymatic treatments:

    • Chondroitinase ABC (removes chondroitin sulfate chains)

    • Hyaluronidase (digests hyaluronan backbone)

    • Phosphatase (removes phosphate groups)

  • Comparison of detection before and after treatment

• Antibody panel approach:

  • Multiple antibodies targeting different HAPLN4 epitopes

  • Domain-specific antibodies (Ig-like domain vs. link domains)

  • Phospho-specific antibodies if available

• Biochemical validation:

  • Immunoprecipitation followed by mass spectrometry

  • Western blotting with and without deglycosylation

  • 2D gel electrophoresis to separate PTM variants

• Controls and analysis:

  • Include recombinant HAPLN4 protein standards

  • Perform double-blinding in analysis

  • Use rigorous statistical testing (paired analysis for treated/untreated)

  • Document all experimental parameters comprehensively

This approach follows the principles of good experimental design, including appropriate controls, randomization, and blinding to minimize bias .

How might HAPLN4 antibodies contribute to understanding age-related changes in brain extracellular matrix?

Strategic approaches for aging studies:

• Age-dependent expression profiling:

  • Compare HAPLN4 levels across multiple age points (young, middle-aged, elderly)

  • Correlate with functional parameters (auditory testing, cognitive measures)

  • Assess region-specific vulnerability to age-related changes

• Combined diffusion-immunohistochemistry approach:

  • Real-time iontophoretic diffusion measurements in different age groups

  • Follow with HAPLN4 immunostaining in the same tissue regions

  • Correlate diffusion parameters with HAPLN4 distribution patterns

• Experimental therapeutic interventions:

  • Enzymatic digestion of PNNs to assess reversibility of age-related changes

  • Viral-mediated restoration of HAPLN4 in aged animals

  • Pharmacological targeting of PNN-related pathways

The evidence from HAPLN4-KO mice suggests that aging is a critical point revealing the effect of HAPLN4 deficiency on extracellular space diffusion. These approaches would extend understanding of how HAPLN4 contributes to brain aging processes .

What experimental approaches would best determine if HAPLN4 could serve as a biomarker for neuropsychiatric disorders?

Multi-level validation strategy:

• Human tissue studies:

  • Post-mortem brain analysis from psychiatric patient cohorts

  • Region-specific quantification of HAPLN4 expression

  • Correlation with neuropathological findings and clinical data

• Cerebrospinal fluid analysis:

  • Development of sensitive ELISA protocols for HAPLN4 detection

  • Cross-validation with multiple antibodies

  • Comparison between patient populations and controls

• Animal model validation:

  • HAPLN4 expression analysis in established psychiatric disorder models

  • Correlation with behavioral phenotypes

  • Pharmacological challenge effects on HAPLN4 levels

• Imaging correlations:

  • PET ligand development for PNN visualization

  • Correlation of HAPLN4 levels with structural and functional neuroimaging

  • Longitudinal imaging to track disease progression

Based on the known association between HAPLN4 expression and gray matter volume reduction in schizophrenia, these approaches could validate HAPLN4 as a potential biomarker for neuropsychiatric conditions .